November 30, 2016 / 11:15 AM / a year ago

BRIEF-Achillion announces initiation of patient dosing by Janssen in phase 2B study

Nov 30 (Reuters) - Achillion Pharmaceuticals Inc

* Achillion announces initiation of patient dosing by Janssen in a global, short treatment-duration phase 2B study of JNJ-4178 in chronic HCV

* An ongoing phase 2A study is assessing JNJ-4178 in patients with or without compensated cirrhosis Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below